Angela B. Smith, MD, MS, discusses how her institution has adjusted how it conducts clinical trials in the COVID-19 era.
In this video, Angela B. Smith, MD, MS, explains how the COVID-19 pandemic has affected patient recruitment for and conducting of clinical trials at her institution. Smith is vice chair of academic affairs, director of urologic oncology, and associate professor of urology at UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.